Loading quotes...

Forecast

The analysts' average price target is €60.16 (+7.77%). The median is €62.85 (+12.59%).

Buy	16
Hold	15
Sell	2

News Go to news feed

Bruker bets on deep tech: semiconductor metrology, defense and fusion research drive orders

Bruker reported at the Wells Fargo Healthcare Conference strong order intake driven by semiconductor metrology, defense/air‑security systems and fusion research, with a book‑to‑bill ratio above 1.0 and organic order growth of more than 10% year‑on‑year. Earnings per share for Q2 2024 were well above consensus and the company’s guidance, supported by cost cuts and tariff/duty differentials. Management warned of longer delivery cycles, so revenues are lagging orders, but expects roughly 5% organic revenue growth for Q4 2024 and sees longer‑term growth potential especially in China, proteomics and AI‑enabled life‑science applications from 2025. Bruker emphasizes the strategic prioritization of margin‑rich deep‑tech areas despite timing delays in revenue realization. » More on de.investing.com
Bruker announces quarterly dividend of $0.05

Bruker’s board declared a quarterly cash dividend of $0.05 per common share, payable October 7, 2026, to shareholders of record at the close of business on September 21, 2026. At a share price of $57.70, the dividend equates to a yield of about 0.35%. Bruker beat adjusted earnings expectations in the second quarter, but missed revenue and issued a cautious outlook; Stifel raised its price target to $50 while keeping its rating at "Hold." » More on de.investing.com
Bruker beats profit forecast for Q2, stock falls after revenue miss

Bruker reported adjusted earnings of $0.49 per share for Q2, well above the consensus estimate of $0.3832, while revenue of $838.5 million missed the estimate of $853.39 million. Improved margins (Non-GAAP gross margin 52.1%, operating margin 14.1%) and cost reductions boosted profitability, but organic revenue growth remained subdued at 2.8%. The stock fell about 16.8% to $53.50 after the announcement as investors weighed the weaker revenue and a cautious near-term outlook. Bruker reiterated full-year EPS guidance of $2.10–$2.15 and expects flat to slightly higher organic revenue growth in Q3 with modest margin pressure, with a more pronounced recovery anticipated in Q4. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Bruker Co. has already paid €0.17 in dividends. The last payout was in October.

Financials

In the last quarter, Bruker Co. had revenue of €734.7M and net profit of -€45.56M

(EUR)	June 2026	YoY
Revenue	734.7M	8.60%
Gross profit	364.5M	20.04%
Net profit	-45.56M	806.62%
EBITDA	15.16M	75.29%

Fundamentals

Metric	Value
Market capitalization	€8.48B
Number of shares	152.36M
52-week high/low	€60.14 - €29.06
Dividend yield	0.31%
Dividends TTM	€0.17
Beta	1.22
P/E ratio	-88.70
PEG ratio	1.01
P/B ratio	3.93
P/S ratio	2.70

Company profile

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

Name	Bruker Co.
CEO	Frank H. Laukien
Headquarters	Billerica, ma USA
Website	bruker.com
Sector	Health Care
Industry	Health Care Equipment & Supplies
IPO	08/04/2000
Employees	11,085